At Ulisse Biomed, the commitment to innovative, state-of-the-art solutions continues.

Our study was recently published in Analytical Chemistry and an international patent application for an evolution of the same technology used in the study.

The article published in the journal presents the work of the Ulisse Biomed team in collaboration with three prestigious universities: the University of Parma, the University of Pisa and the University of Rome Tor Vergata.

An interesting application of the nano-switch platform has been developed for Therapeutic Drug Monitoring (TDM) of monoclonal antibodies (mAbs) used in chronic inflammatory diseases, a field in which dose optimisation is crucial to reduce side effects and therapeutic failures.

The system exploits conjugation between whole proteins and DNA, through the use of a highly innovative technology that has recently emerged.

It is a modular and scalable solution for TDM, potentially applicable to different biological drug targets and classes. The integration of ADA-responsive sensitivity and the absence of washing make it a very promising tool in clinical settings requiring real-time personalised monitoring.

The development of this technology led to the international patent application published in early April.

We continue our efforts to contribute to scientific progress through cutting-edge solutions in the field of molecular biology.